Literature DB >> 20091089

Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician.

S Michael Gharacholou1, Renato D Lopes, Jeffrey B Washam, L Kristin Newby, Stefan K James, John H Alexander.   

Abstract

The use of anticoagulant and antiplatelet therapy during the management of acute coronary syndromes (ACS) has been associated with improvements in short- and long-term clinical outcomes, regardless of whether patients are managed conservatively or with acute coronary revascularization. Translating the existing evidence for selection of the most appropriate antithrombotic strategy has been summarized in available guideline recommendations. Given the breadth of antithrombotic recommendations across existing U.S. and European guidelines, synthesis of these recommendations for practicing clinicians who treat patients with ACS are increasingly desired. Providing a summary of the similarities across guidelines while noting the areas where divergence exists becomes an important facet in translating optimal antithrombotic management in ACS for the treating clinician. This review highlights the important aspects of clinical practice guidelines that practicing physicians should consider when selecting antithrombotic therapies to reduce ischemic risk while minimizing hemorrhagic risk across all ACS subtypes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20091089     DOI: 10.1007/s11239-009-0437-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  58 in total

Review 1.  Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.

Authors:  R Collins; R Peto; C Baigent; P Sleight
Journal:  N Engl J Med       Date:  1997-03-20       Impact factor: 91.245

2.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors:  C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

3.  Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction.

Authors:  Matthew T Roe; Lori S Parsons; Charles V Pollack; John G Canto; Hal V Barron; Nathan R Every; William J Rogers; Eric D Peterson
Journal:  Arch Intern Med       Date:  2005-07-25

4.  Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy.

Authors:  K W Mahaffey; C B Granger; R Collins; C M O'Connor; E M Ohman; S D Bleich; J J Col; R M Califf
Journal:  Am J Cardiol       Date:  1996-03-15       Impact factor: 2.778

5.  Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.

Authors:  Harvey D White; Neal S Kleiman; Kenneth W Mahaffey; Yuliya Lokhnygina; Karen S Pieper; Karen Chiswell; Marc Cohen; Robert A Harrington; Derek P Chew; John L Petersen; Lisa G Berdan; Philip E G Aylward; Christopher C Nessel; James J Ferguson; Robert M Califf
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

6.  Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Robert A Harrington; Richard C Becker; Christopher P Cannon; David Gutterman; A Michael Lincoff; Jeffrey J Popma; Gabriel Steg; Gordon H Guyatt; Shaun G Goodman
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 7.  Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.

Authors:  John L Petersen; Kenneth W Mahaffey; Vic Hasselblad; Elliott M Antman; Marc Cohen; Shaun G Goodman; Anatoly Langer; Michael A Blazing; Anne Le-Moigne-Amrani; James A de Lemos; Christopher C Nessel; Robert A Harrington; James J Ferguson; Eugene Braunwald; Robert M Califf
Journal:  JAMA       Date:  2004-07-07       Impact factor: 56.272

8.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).

Authors:  Elliott M Antman; Daniel T Anbe; Paul Wayne Armstrong; Eric R Bates; Lee A Green; Mary Hand; Judith S Hochman; Harlan M Krumholz; Frederick G Kushner; Gervasio A Lamas; Charles J Mullany; Joseph P Ornato; David L Pearle; Michael A Sloan; Sidney C Smith; Joseph S Alpert; Jeffrey L Anderson; David P Faxon; Valentin Fuster; Raymond J Gibbons; Gabriel Gregoratos; Jonathan L Halperin; Loren F Hiratzka; Sharon Ann Hunt; Alice K Jacobs
Journal:  Circulation       Date:  2004-08-03       Impact factor: 29.690

9.  Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative.

Authors:  Adam H Skolnick; Karen P Alexander; Anita Y Chen; Matthew T Roe; Charles V Pollack; E Magnus Ohman; John S Rumsfeld; W Brian Gibler; Eric D Peterson; David J Cohen
Journal:  J Am Coll Cardiol       Date:  2007-04-16       Impact factor: 24.094

10.  Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction.

Authors:  Mark Y Chan; Jie L Sun; L Kristin Newby; Linda K Shaw; Min Lin; Eric D Peterson; Robert M Califf; David F Kong; Matthew T Roe
Journal:  Circulation       Date:  2009-06-08       Impact factor: 29.690

View more
  4 in total

Review 1.  Cost effectiveness of anticoagulation in acute coronary syndromes.

Authors:  Jaime Latour-Pérez; Eva de-Miguel-Balsa
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

Review 2.  Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus.

Authors:  S Michael Gharacholou; Brenda J Larson; Christian C Zuver; Ryan J Wubben; Giorgio Gimelli; Amish N Raval
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

Review 3.  Ticagrelor: a review of its use in the management of acute coronary syndromes.

Authors:  Emma D Deeks
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 4.  Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.

Authors:  Renli Teng
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.